Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre for Addiction and Mental Health
With
University Health Network, Toronto
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
outpatients
voluntary and competent to consent
Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of MDD, single, recurrent
between ages 18-65
failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of ≥ 3 in the current episode or have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF 1 or 2)
have a score of ≥ 18 on the HAMD-17 item
have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening
able to adhere to the treatment schedule
Pass the TMS adult safety screening (TASS) questionnaire
have normal thyroid functioning based on pre-study blood work
You may not be if
have a history of substance dependence or abuse within the last 3 months
have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump
have active suicidal intent
are pregnant
have a lifetime MINI diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic symptoms
have a MINI diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia assessed by a study investigator to be primary and causing greater impairment than MDD